Clinical trials
Amyloid clinical trials
Below are recruiting amyloid clinical trials, each written for real people, not researchers. We’re tracking 87 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07250035RecruitingPhase 3
Chinese herb trial for brain bleed linked to amyloid angiopathy
This trial tests a traditional Chinese medicine called Jiedu Huayu to see if it helps people recover from a brain bleed caused by a condition where proteins build up in blood vessel walls (cerebral amyloid angiopathy). The goal is to improve outcomes without surgery.
BeijingAges 50–90 - NCT07222930Enrolling by invitation
Learning about amyloid and tau test results
This study helps people understand their results from brain scans that measure amyloid and tau proteins, which are linked to Alzheimer's disease. It is for adults 45 and older who are part of specific Alzheimer's research programs and have no dementia diagnosis.
Madison, WisconsinAges 45–89 - NCT05667493Enrolling by invitationPhase 3
Long-term safety follow-up for eplontersen in ATTR heart disease
This is a long-term study to check the safety of eplontersen over time in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). It is mainly for people who already took the study medication before, or who joined an earlier related study and are doing well.
Scottsdale, ArizonaAges 18 years+ - NCT05448768Enrolling by invitation
Testing brain stimulation in people with mild memory problems
This study tests a brain stimulation approach (TBS) to see if it can improve thinking and memory in people with mild cognitive impairment. It may also explore why it works by looking at brain-related measurements after TBS.
TaoyuanAges 50–90 - NCT07766135Recruiting
Liver and blood clotting in heart amyloidosis
This study looks at how the liver and blood clotting are affected in people with a type of heart disease called transthyretin amyloidosis. It may help doctors better understand and manage this condition.
Messina, SicilyAges 18 years+ - NCT07099053Recruiting
Brain scan study for aging adults in Baltimore
This study uses a special brain scan (amyloid PET) to look at brain changes in healthy older adults. It may help researchers learn more about aging and memory loss.
Baltimore, MarylandAges 55–110 - NCT06101108Recruiting
Early heart screening in back surgery patients
This trial checks people having back surgery for spinal stenosis to see if they have an early sign of heart amyloidosis (a protein buildup in the heart). The goal is to find this condition early so it can be treated before it causes problems.
BrugesAges 60 years+ - NCT07589595RecruitingPhase 2
Donanemab for Early Cognitive Decline with Lewy Bodies
This study tests donanemab, an investigational drug designed to target amyloid proteins in the brain that may contribute to cognitive decline in people with early dementia with Lewy bodies. The trial aims to see if this treatment can slow cognitive decline and help preserve thinking and memory.
Chandler, ArizonaAges 55–85 - NCT06291805Recruiting
Understanding wtATTR-CM heart disease (TRACE 1)
This study aims to better understand a type of heart disease called wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). It will compare people with this condition to a control group without known heart disease to identify key features.
Aarhus, Arrhus NAges 18 years+ - NCT07298044RecruitingPhase 4
Switching from tafamidis to acoramidis for heart condition
This study checks how levels of a protein called transthyretin change in your blood when you switch from tafamidis to acoramidis. It is for people with a specific type of heart disease caused by abnormal protein buildup.
Sankt Pölten, Lower AustriaAges 18–90 - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
La Jolla, CaliforniaAges 18–75 - NCT07695701RecruitingPhase 4
Heart imaging study for a new ATTR-CM treatment
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
St Louis, MissouriAges 18–80 - NCT07398950Recruiting
AI screening for a heart condition called ATTR-CM
This study uses artificial intelligence (AI) to look at your heart tests (ECG and echo) and find people who might have a specific heart muscle disease called ATTR-CM. The goal is to catch it earlier so treatment can start sooner.
New Haven, ConnecticutAges 18 years+ - NCT05951816RecruitingPhase 1
Imaging study for amyloidosis in heart and body
This study tests a new imaging agent (99mTc-p5+14) that helps doctors see amyloid deposits in the body, especially in the heart. It is for healthy volunteers and people with AL or ATTR amyloidosis that has affected the heart.
Knoxville, TennesseeAges 18 years+ - NCT07560306RecruitingPhase 3
New Heart Scan to Detect Blood Clots in Amyloid Heart Disease
This study tests a new type of imaging scan ([64Cu]FBP8 PET) to detect blood clots that may form in the heart's left atrial appendage (a small pouch in the heart) in patients with amyloid cardiomyopathy (a disease where abnormal protein builds up in heart muscle) who also have irregular heartbeat. The scan may help doctors catch clots earlier and prevent strokes.
Boston, MassachusettsAges 18 years+ - NCT07224672RecruitingPhase 2
Study of a drug combo for newly diagnosed AL amyloidosis
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
Rochester, MinnesotaAges 18 years+ - NCT03761381Recruiting
Eye scan study for mild Alzheimer’s and memory changes
This study uses detailed eye imaging (an eye scan) to look for signs related to probable Alzheimer’s disease and mild dementia. It may help researchers understand whether eye scans can reflect brain changes and improve detection.
Portland, OregonAges 55 years+ - NCT03860857RecruitingPhase 3
Study biomarkers in memory aging and brain health
This Phase 3 study looks for blood/brain “biomarkers” linked to aging, memory changes, and early brain degeneration. It may help researchers better identify who is at risk and how biology relates to thinking and memory, using brain scans and thinking tests.
Irvine, CaliforniaAges 60 years+ - NCT04776824Recruiting
Swiss registry for people with amyloidosis and possible heart involvement
This trial is a registry that collects health information from people with amyloidosis, including cases where the heart may be involved. Sharing your medical details can help researchers learn how this condition affects patients and may guide future care.
BaselAges 18 years+ - NCT07110844RecruitingPhase 2
Teclistamab with Daratumumab for Newly Diagnosed AL Amyloidosis
This trial tests a combination of two drugs (teclistamab and daratumumab) for people with AL amyloidosis who have not had prior treatment. The goal is to see if this combination can safely and effectively reduce the abnormal protein deposits in organs.
Boston, MassachusettsAges 18–100 - NCT05059158Recruiting
Study how the brain clears amyloid in Alzheimer’s
This trial studies how the brain removes amyloid-β, a protein linked to Alzheimer’s disease. It may help researchers understand what’s happening in people with mild memory impairment or Alzheimer’s, and guide better treatments in the future.
München, BavariaAges 50–85 - NCT05489549Recruiting
Study of heart amyloid risk in people with TTR gene variants
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
New York, New YorkAges 30–80 - NCT05709314RecruitingPhase 2
AMDX-2011P for cerebral amyloid angiopathy (CAA
This Phase 2 study tests AMDX-2011P to see if it can help people with cerebral amyloid angiopathy (CAA), a condition where abnormal protein affects blood vessels in the brain. You may be able to join if you have confirmed or likely CAA and a recent brain MRI showing changes from CAA.
Phoenix, ArizonaAges 18 years+ - NCT05797857Recruiting
Exercise program for transthyretin heart amyloidosis
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
Boston, MassachusettsAges 60–90
Hear when a new Amyloid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for amyloid?
- Yes. Clin2 currently lists 87 recruiting amyloid studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a amyloid trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a amyloid trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.